nexium 40 mg
orifarm as - esomeprazolmagnesiumtrihydrat - enterotablett - 40 mg
nexium 20 mg
farmagon - esomeprazolmagnesiumtrihydrat - enterotablett - 20 mg
nexium 40 mg
farmagon - esomeprazolmagnesiumtrihydrat - enterotablett - 40 mg
nexium 40 mg
orifarm as - esomeprazolmagnesiumtrihydrat - enterotablett - 40 mg
vimovo 500 mg / 20 mg
grünenthal gmbh (1) - naproksen / esomeprazolmagnesiumtrihydrat - tablett med modifisert frisetting - 500 mg / 20 mg
nexium 40 mg
farmagon - esomeprazol - pulver til injeksjons-/infusjonsvæske, oppløsning - 40 mg
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
noxafil 300 mg
orifarm as - posakonazol - konsentrat til infusjonsvæske, oppløsning - 300 mg
edurant
janssen-cilag international n.v. - rilpivirinhydroklorid - hiv-infeksjoner - antivirale midler til systemisk bruk - edurant, er i kombinasjon med andre antiretrovirale legemidler, indisert for behandling av humant immunsviktvirus type 1 (hiv‑1)-infeksjon i antiretroviral treatment‑naïve pasienter 12 år og eldre med en viral belastning ≤ 100.000 hiv‑1 rna kopier/ml. som med andre antiretroviral legemidler, genotypic motstand testing som bør styre bruken av edurant.
escitalopram actavis 5 mg
actavis group ptc ehf - escitalopramoksalat - tablett, filmdrasjert - 5 mg